What is Zacks Research's Forecast for BMRN Q2 Earnings?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research reduced their Q2 2026 earnings estimates for BioMarin Pharmaceutical in a research report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $0.99 for the quarter, down from their prior estimate of $1.00. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's Q3 2026 earnings at $1.05 EPS, Q4 2026 earnings at $1.13 EPS, FY2026 earnings at $4.09 EPS and FY2027 earnings at $4.79 EPS.

Several other research analysts also recently issued reports on the stock. Wedbush reiterated an "outperform" rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Scotiabank upped their price objective on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a research report on Thursday, February 20th. Piper Sandler lifted their target price on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a report on Thursday, February 20th. Citigroup upped their price target on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Finally, Oppenheimer raised BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price objective on the stock in a research report on Monday, February 24th. Seven equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Remove Ads

BioMarin Pharmaceutical Stock Up 1.9 %

Shares of BMRN traded up $1.35 during trading hours on Monday, hitting $72.83. The company had a trading volume of 1,364,576 shares, compared to its average volume of 1,785,404. BioMarin Pharmaceutical has a 52-week low of $60.63 and a 52-week high of $94.85. The firm has a fifty day moving average price of $67.03 and a 200-day moving average price of $67.81. The stock has a market capitalization of $13.89 billion, a price-to-earnings ratio of 33.10, a P/E/G ratio of 0.61 and a beta of 0.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. The company had revenue of $747.31 million during the quarter, compared to analyst estimates of $711.05 million.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several large investors have recently added to or reduced their stakes in BMRN. Oregon Public Employees Retirement Fund lifted its holdings in shares of BioMarin Pharmaceutical by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company's stock worth $2,546,000 after acquiring an additional 164 shares during the last quarter. Fifth Third Bancorp grew its position in BioMarin Pharmaceutical by 13.9% in the 4th quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock valued at $89,000 after acquiring an additional 165 shares during the last quarter. Advisors Asset Management Inc. increased its stake in BioMarin Pharmaceutical by 1.6% in the third quarter. Advisors Asset Management Inc. now owns 11,451 shares of the biotechnology company's stock worth $805,000 after purchasing an additional 180 shares during the period. Freedom Investment Management Inc. lifted its position in shares of BioMarin Pharmaceutical by 3.8% during the fourth quarter. Freedom Investment Management Inc. now owns 5,022 shares of the biotechnology company's stock worth $330,000 after purchasing an additional 184 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its stake in shares of BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 186 shares during the period. 98.71% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CAO Erin Burkhart sold 1,344 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the sale, the chief accounting officer now directly owns 13,105 shares in the company, valued at approximately $896,119.90. This represents a 9.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.